Catalog No.: PC-20351Not For Human Use, Lab Use Only.
IMMH002 is a potent, selective and orally active S1P1 agonist, IMMH002 can be transformed to IMMH002-P in vivo, IMMH002-P activates S1P1, S1P4, and S1P5 with 12.4, 19.8 and 29.4 nM respectively.
IMMH002 is a potent, selective and orally active S1P1 agonist, IMMH002 can be transformed to IMMH002-P in vivo, IMMH002-P activates S1P1, S1P4, and S1P5 with 12.4, 19.8 and 29.4 nM respectively.
IMMH002-P only showed mild activation effect on S1P2 and S1P3 with EC50 >5000 nM.
IMMH002-P induces activation and internalization of S1P1.
IMMH002 (0.3, 1 and 3 mg/kg, p.o.) dramatically decreases the number of peripheral blood lymphocytes, alleviates sodium dodecyl sulphate (SDS)-induced skin irritation in mice in SD rats.
IMMH002 (1.2, 2.4 mg/kg) ameliorates propranolol induced psoriasis in guinea pig.
